The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.

BACKGROUND Chronic obstructive pulmonary disease (COPD) is characterized by an incompletely reversible limitation in airflow. A physiological variable--the forced expiratory volume in one second (FEV1)--is often used to grade the severity of COPD. However, patients with COPD have systemic manifestations that are not reflected by the FEV1. We hypothesized that a multidimensional grading system that assessed the respiratory and systemic expressions of COPD would better categorize and predict outcome in these patients. METHODS We first evaluated 207 patients and found that four factors predicted the risk of death in this cohort: the body-mass index (B), the degree of airflow obstruction (O) and dyspnea (D), and exercise capacity (E), measured by the six-minute-walk test. We used these variables to construct the BODE index, a multidimensional 10-point scale in which higher scores indicate a higher risk of death. We then prospectively validated the index in a cohort of 625 patients, with death from any cause and from respiratory causes as the outcome variables. RESULTS There were 25 deaths among the first 207 patients and 162 deaths (26 percent) in the validation cohort. Sixty-one percent of the deaths in the validation cohort were due to respiratory insufficiency, 14 percent to myocardial infarction, 12 percent to lung cancer, and 13 percent to other causes. Patients with higher BODE scores were at higher risk for death; the hazard ratio for death from any cause per one-point increase in the BODE score was 1.34 (95 percent confidence interval, 1.26 to 1.42; P<0.001), and the hazard ratio for death from respiratory causes was 1.62 (95 percent confidence interval, 1.48 to 1.77; P<0.001). The C statistic for the ability of the BODE index to predict the risk of death was larger than that for the FEV1 (0.74 vs. 0.65). CONCLUSIONS The BODE index, a simple multidimensional grading system, is better than the FEV1 at predicting the risk of death from any cause and from respiratory causes among patients with COPD.

[1]  Jordi Alonso,et al.  Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[2]  Toru Oga,et al.  Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. , 2002, Chest.

[3]  Byung-Ho Nam,et al.  Discrimination Index, the Area Under the ROC Curve , 2002 .

[4]  ATS statement: guidelines for the six-minute walk test. , 2002, American journal of respiratory and critical care medicine.

[5]  V. Hasselblad,et al.  Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. , 2001, The American journal of cardiology.

[6]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[7]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[8]  M. Niederman,et al.  Acute exacerbation of COPD: factors associated with poor treatment outcome. , 2000, Chest.

[9]  M. Fujita,et al.  Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. , 2000, American journal of respiratory and critical care medicine.

[10]  J. Vestbo,et al.  Prognostic value of nutritional status in chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[11]  J. Wilson,et al.  Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. , 1999, Chest.

[12]  R. Zuwallack,et al.  Pulmonary rehabilitation - 1999 , 1999 .

[13]  M. Tsukino,et al.  Comparison of Discriminative Properties among Disease-specific Questionnaires for Measuring Health-related Quality of Life in Patients with Chronic Obstructive Pulmonary Disease , 1998 .

[14]  E. Wouters,et al.  Weight Loss Is a Reversible Factor in the Prognosis of Chronic Obstructive Pulmonary Disease , 1998 .

[15]  M. Ferrer,et al.  Chronic Obstructive Pulmonary Disease Stage and Health-Related Quality of Life , 1997, Annals of Internal Medicine.

[16]  Alan D. Lopez,et al.  Mortality by cause for eight regions of the world: Global Burden of Disease Study , 1997, The Lancet.

[17]  D A Redelmeier,et al.  Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. , 1997, American journal of respiratory and critical care medicine.

[18]  J. Wain,et al.  Preoperative predictors of operative morbidity and mortality in COPD patients undergoing bilateral lung volume reduction surgery. , 1997, Chest.

[19]  M. Decramer,et al.  Muscle weakness is related to utilization of health care resources in COPD patients. , 1997, The European respiratory journal.

[20]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[21]  R. Zuwallack,et al.  Variables related to increased mortality following out-patient pulmonary rehabilitation. , 1996, The European respiratory journal.

[22]  Daniel B. Mark,et al.  TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .

[23]  J C Yernault,et al.  Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. , 1995, The European respiratory journal.

[24]  J. Gold,et al.  Validation of a combined comorbidity index. , 1994, Journal of clinical epidemiology.

[25]  H. Magnussen,et al.  Factor analysis of exercise capacity, dyspnoea ratings and lung function in patients with severe COPD. , 1994, The European respiratory journal.

[26]  A. Miller,et al.  Lung function testing: selection of reference values and interpretative strategies. , 1992, The American review of respiratory disease.

[27]  A. Harver,et al.  A factor analysis of dyspnea ratings, respiratory muscle strength, and lung function in patients with chronic obstructive pulmonary disease. , 1992, The American review of respiratory disease.

[28]  R. Kaplan,et al.  Use of factor analysis to consolidate multiple outcome measures in chronic obstructive pulmonary disease. , 1991, Journal of clinical epidemiology.

[29]  C K Wells,et al.  Evaluation of clinical methods for rating dyspnea. , 1988, Chest.

[30]  N. Anthonisen,et al.  Prognosis in chronic obstructive pulmonary disease. , 1990, The American review of respiratory disease.

[31]  C. Wells,et al.  The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. , 1984, Chest.

[32]  I Grant,et al.  Psychologic effects of continuous and nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease. , 1983, Archives of internal medicine.

[33]  Intermittent positive pressure breathing therapy of chronic obstructive pulmonary disease. A clinical trial. , 1983, Annals of internal medicine.

[34]  D. Cox.  Regression Models and Life-Tables , 1972 .

[35]  A. Renzetti.  Prognosis in chronic obstructive pulmonary disease. , 1967, The Medical clinics of North America.